These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 22096987)
21. MAP of F1 and V antigens from Yersinia pestis astride innate and adaptive immune response. Rai R; Das B; Choudhary N; Talukdar A; Rao DN Microb Pathog; 2015 Oct; 87():13-20. PubMed ID: 26188288 [TBL] [Abstract][Full Text] [Related]
22. Small protective fragments of the Yersinia pestis V antigen. Vernazza C; Lingard B; Flick-Smith HC; Baillie LW; Hill J; Atkins HS Vaccine; 2009 May; 27(21):2775-80. PubMed ID: 19366573 [TBL] [Abstract][Full Text] [Related]
23. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity. Eyles JE; Butcher WA; Titball RW; Hill J Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388 [TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV. DeBord KL; Anderson DM; Marketon MM; Overheim KA; DePaolo RW; Ciletti NA; Jabri B; Schneewind O Infect Immun; 2006 Aug; 74(8):4910-4. PubMed ID: 16861680 [TBL] [Abstract][Full Text] [Related]
25. The LcrG Tip Chaperone Protein of the Yersinia pestis Type III Secretion System Is Partially Folded. Chaudhury S; de Azevedo Souza C; Plano GV; De Guzman RN J Mol Biol; 2015 Sep; 427(19):3096-109. PubMed ID: 26259880 [TBL] [Abstract][Full Text] [Related]
26. A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin/F1/V, in healthy adult volunteers (DMID 08-0066). Frey SE; Lottenbach K; Graham I; Anderson E; Bajwa K; May RC; Mizel SB; Graff A; Belshe RB Vaccine; 2017 Dec; 35(48 Pt B):6759-6765. PubMed ID: 29037578 [TBL] [Abstract][Full Text] [Related]
27. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836 [TBL] [Abstract][Full Text] [Related]
29. Structural and functional properties of Yersinia pestis Caf1 capsular antigen and their possible role in fulminant development of primary pneumonic plague. Abramov VM; Vasiliev AM; Khlebnikov VS; Vasilenko RN; Kulikova NL; Kosarev IV; Ishchenko AT; Gillespie JR; Millett IS; Fink AL; Uversky VN J Proteome Res; 2002; 1(4):307-15. PubMed ID: 12645886 [TBL] [Abstract][Full Text] [Related]
30. Immunogenesis in White Mice Infected with Yersinia pestis with Different Plasmid Composition. Balakhonov SV; Vityazeva SA; Dubrovina VI; Starovoitova TP; Mukhturgin GB; Ivanova TA; Korytov KM; Kolesnikov SI Bull Exp Biol Med; 2017 Feb; 162(4):470-473. PubMed ID: 28243913 [TBL] [Abstract][Full Text] [Related]
31. Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits. Eyles JE; Williamson ED; Spiers ID; Stagg AJ; Jones SM; Alpar HO J Control Release; 2000 Jan; 63(1-2):191-200. PubMed ID: 10640592 [TBL] [Abstract][Full Text] [Related]
32. Cell-mediated immune response to epitopic MAP (multiple antigen peptide) construct of LcrV antigen of Yersinia pestis in murine model. Shreewastav RK; Ali R; Uppada JB; Rao DN Cell Immunol; 2012; 278(1-2):55-62. PubMed ID: 23121976 [TBL] [Abstract][Full Text] [Related]
33. Dissecting the structure of LcrV from Yersinia pestis, a truly unique virulence protein. Nilles ML Structure; 2004 Mar; 12(3):357-8. PubMed ID: 15016350 [No Abstract] [Full Text] [Related]
34. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Chattopadhyay A; Park S; Delmas G; Suresh R; Senina S; Perlin DS; Rose JK Vaccine; 2008 Nov; 26(50):6329-37. PubMed ID: 18832004 [TBL] [Abstract][Full Text] [Related]
35. Immunological characterisation of sub-units of the Yersinia type III secretion apparatus. Hill J; Underwood CD; Sundberg L; Aström H; Leary SE; Forsberg A; Titball RW Adv Exp Med Biol; 2003; 529():415-7. PubMed ID: 12756800 [No Abstract] [Full Text] [Related]
36. Antigenic profiling of yersinia pestis infection in the Wyoming coyote (Canis latrans). Vernati G; Edwards WH; Rocke TE; Little SF; Andrews GP J Wildl Dis; 2011 Jan; 47(1):21-9. PubMed ID: 21269993 [TBL] [Abstract][Full Text] [Related]
37. Expression of Yersinia pestis V antigen in attenuated salmonella typhimurium: development of a novel vaccine for plague. Leary SE; Eley SM; Williamson ED; Titball RW Contrib Microbiol Immunol; 1995; 13():216-7. PubMed ID: 8833838 [No Abstract] [Full Text] [Related]
39. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague. Levy Y; Flashner Y; Tidhar A; Zauberman A; Aftalion M; Lazar S; Gur D; Shafferman A; Mamroud E Vaccine; 2011 Sep; 29(40):6866-73. PubMed ID: 21803090 [TBL] [Abstract][Full Text] [Related]
40. [Development and testing of an enzyme immunoassay-based monoclonal test system for the detection of the Yersinia pestis V antigen]. Ivashchenko TA; Belova EV; Dentovskaia SV; Bel'kova SA; Balakhonov SV; Ignatov SG; Shemiakin IG Prikl Biokhim Mikrobiol; 2014; 50(2):211-8. PubMed ID: 25272741 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]